Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-RO5323441 PET imaging in recurrent glioblastoma treated with bevacizumab
2011-004974-27Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of THR-317 in glioblastoma (GBM) and malignant glioma, sponsored by University Medical Center Groningen. Primary endpoints: Tumor uptake and biodistribution of 89Zr-RO5323441 and Effect of bevacizumab on 89Zr-RO5323441 uptake. Started Nov 2011; status: completed.
02
Drugs
THR-317
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on 2011-004974-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004974-27.